Which has the lower trailing P/E, ANIP or ASTH?

ANIP has the lower trailing P/E: ANIP trades at 15.45 and ASTH at 45.26. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ANIP or ASTH?

Over the past five years, ASTH grew revenue faster — ANIP at a 35.61% CAGR versus ASTH at 53.77%.

Is ANIP or ASTH more profitable?

ANIP runs the higher net margin — ANIP at 10.82% versus ASTH at 1.05%.

How have ANIP and ASTH total returns compared?

Over the past 10 years, ANIP delivered 0.51% and ASTH delivered 25.17% annualized total return. Past performance doesn't predict future results.

ANI Pharmaceuticals, Inc. (ANIP) vs Astrana Health, Inc. (ASTH)

A side-by-side comparison of ANI Pharmaceuticals, Inc. and Astrana Health, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ANIP

ANI Pharmaceuticals, Inc.

$1.63B

$71.52HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

ASTH

Astrana Health, Inc.

$1.83B

$37.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — ANIP vs ASTH

growth of $100 · dividends reinvested · last 10y

ANIP +5.2% (+0.5%/yr)ASTH +824.9% (+24.9%/yr)ASTH compounded faster over this window

Log scale — wide-divergence pair

ANIP ASTH

ANIP vs ASTH: by the numbers

•ASTH is the larger company ($1.83B vs $1.63B market cap).
•ANIP trades at the lower trailing earnings multiple (15.45 vs 45.26 P/E), one valuation lens rather than an overall verdict.
•ANIP converts more revenue to profit (10.82% vs 1.05% net margin).
•ASTH grew revenue faster over the past five years (53.77% vs 35.61% CAGR).

Metrics side by side

Valuation

Metric	ANIP	ASTH
P/E ratio	15.45	45.26
Forward P/E	7.71	26.47
P/S ratio	1.66	0.48
P/B ratio	2.72	2.21
EV / EBITDA	6.76	13.48
FCF yield	N/A	8.64%

Profitability

Metric	ANIP	ASTH
Gross margin	51.01%	9.22%
Operating margin	15.35%	2.61%
Net margin	10.82%	1.05%
ROE	17.72%	4.88%
ROIC	9.26%	4.13%

Growth (annualized)

Metric	ANIP	ASTH
Revenue CAGR (5Y)	35.61%	53.77%
EPS CAGR (5Y)	N/A	-15.06%
FCF CAGR (5Y)	N/A	18.35%
Total return CAGR (5Y)	16.86%	-16.52%

Frequently asked

Which has the lower trailing P/E, ANIP or ASTH?: ANIP has the lower trailing P/E: ANIP trades at 15.45 and ASTH at 45.26. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ANIP or ASTH?: Over the past five years, ASTH grew revenue faster — ANIP at a 35.61% CAGR versus ASTH at 53.77%.
Is ANIP or ASTH more profitable?: ANIP runs the higher net margin — ANIP at 10.82% versus ASTH at 1.05%.
How have ANIP and ASTH total returns compared?: Over the past 10 years, ANIP delivered 0.51% and ASTH delivered 25.17% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ANIP analysis Full ASTH analysis Interactive comparison tool

Dig into the metrics

ANI Pharmaceuticals P/E ratio Astrana Health P/E ratio ANI Pharmaceuticals ROE Astrana Health ROE ANI Pharmaceuticals operating margin Astrana Health operating margin ANI Pharmaceuticals revenue growth Astrana Health revenue growth ANI Pharmaceuticals free cash flow Astrana Health free cash flow

ANI Pharmaceuticals & Astrana Health appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.